Total Valuation
GlobeStar Therapeutics has a market cap or net worth of $1.24K. The enterprise value is $490.12K.
Market Cap$1.24K
Enterprise Value$490.12K
Share Statistics
GlobeStar Therapeutics has 1,241,105,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,241,105,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GlobeStar Therapeutics’s return on equity (ROE) is 1.36 and return on invested capital (ROIC) is 174.56%.
Return on Equity (ROE)1.36
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)174.56%
Return on Capital Employed (ROCE)1.30
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GlobeStar Therapeutics is ―. GlobeStar Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio-1.04
Price to Fair Value-1.04
Price to FCF-7.24
Price to Operating Cash Flow-0.40
PEG Ratio0.00
Income Statement
In the last 12 months, GlobeStar Therapeutics had revenue of 0.00 and earned -1.95M in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income-1.86M
Pretax Income-1.95M
Net Income-1.95M
EBITDA6.72K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -148.28K and capital expenditures 4.00, giving a free cash flow of -148.28K billion.
Operating Cash Flow-148.28K
Free Cash Flow-148.28K
Free Cash Flow per Share>-0.01
Dividends & Yields
GlobeStar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta13.21
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
GlobeStar Therapeutics upcoming earnings date is Feb 15, 2018, After Close (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateFeb 15, 2018
Ex-Dividend Date―
Financial Position
GlobeStar Therapeutics as a current ratio of 0.00, with Debt / Equity ratio of -25.53%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap0.25
Net Debt to EBITDA54.43
Interest Coverage Ratio-20.35
Taxes
In the past 12 months, GlobeStar Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
GlobeStar Therapeutics EV to EBITDA ratio is 275.91, with an EV/FCF ratio of -9.02.
EV to Sales0.00
EV to EBITDA275.91
EV to Free Cash Flow-9.02
EV to Operating Cash Flow-9.02
Balance Sheet
GlobeStar Therapeutics has $41.00 in cash and marketable securities with $329.05K in debt, giving a net cash position of -$329.01K billion.
Cash & Marketable Securities$41.00
Total Debt$329.05K
Net Cash-$329.01K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for GlobeStar Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―